Here you can see and modify the cookie settings of various tools used on and related subdomains.

Save settings
Advantage Austria Show navigation

Intercell Announces FDA Approval of Vaccine against Japanese Encephalitis –

April 7, 2009

Successful Collaboration of the Austrian company with the U.S. Army

In March 2009 the U.S. Food and Drug Administration approved Intercell's new vaccine against Japanese encephalitis for adult travelers and military personnel. The vaccine is a result of collaboration between Intercell and the Walter Reed Army Institute of Research WRAIR) in the U.S.

“The FDA approval of IXIARO is an excellent example of what can be achieved when industry and government work together towards an important common goal”, Intercell’s CEO Gerd Zettlmeissl said. “Intercell looks forward to supplying this novel vaccine to the U.S military for use in their JE immunization program". The company acknowledged that the expert scientists at the Walter Reed Army Institute of Research (WRAIR) made a significant contribution towards development of the vaccine. The total development time of this vaccine was more than 10 years.

IXIARO is a purified, inactivated product for active immunization against viral infections of Japanese encephalitis. IXIARO is manufactured at Intercell’s proprietary manufacturing facility in Scotland and is prepared using modern tissue culture rather than live organisms.
Intercell will directly distribute and market IXIARO to the U.S. military, while such functions will be handled by Novartis Vaccines USA to the private market.

Japanese encephalitis is a mosquito-borne infection that strikes approximately 50,000 persons per year and causes 15,000 deaths. The disease is most common in several developing countries in Asia, including India and China. JE causes death in one out of every three people with overt encephalitis and one-half of survivors develop permanent brain damage. No treatment is currently available for JE and only vaccination effectively prevents the disease.

More info: